Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Toni K. Choueiri(Dana-Farber/Harvard Cancer Center), Colin Hessel(Exelixis (United States)), Susan Halabi(Duke University), Ben L. Sanford(Duke University), M. Dror Michaelson(Massachusetts General Hospital), Olwen Hahn, Meghara Walsh(Dana-Farber/Harvard Cancer Center), Thomas Olencki(The Ohio State University), Joel Picus(Washington University in St. Louis), Eric J. Small(UCSF Helen Diller Family Comprehensive Cancer Center), Shaker R. Dakhil(Wichita State University), Darren R. Feldman(Memorial Sloan Kettering Cancer Center), Milan Mangeshkar(Exelixis (United States)), Christian Scheffold(Exelixis (United States)), Daniel J. George(Duke Medical Center), Michael J. Morris(Memorial Sloan Kettering Cancer Center)
Cited by 397Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis